Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 8.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 809,934 shares of the company’s stock after buying an additional 60,675 shares during the period. Dimensional Fund Advisors LP owned about 2.93% of Castle Biosciences worth $17,631,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. American Century Companies Inc. raised its stake in Castle Biosciences by 12.9% in the second quarter. American Century Companies Inc. now owns 42,818 shares of the company’s stock valued at $932,000 after buying an additional 4,898 shares in the last quarter. Acadian Asset Management LLC raised its stake in Castle Biosciences by 33.0% in the second quarter. Acadian Asset Management LLC now owns 280,497 shares of the company’s stock valued at $6,101,000 after buying an additional 69,673 shares in the last quarter. Rhumbline Advisers raised its stake in Castle Biosciences by 7.7% in the second quarter. Rhumbline Advisers now owns 41,896 shares of the company’s stock valued at $912,000 after buying an additional 2,988 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in shares of Castle Biosciences during the second quarter worth about $2,102,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Castle Biosciences by 10.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after purchasing an additional 952 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Castle Biosciences

In related news, COO Kristen M. Oelschlager sold 2,793 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $22.06, for a total value of $61,613.58. Following the transaction, the chief operating officer now owns 145,825 shares in the company, valued at $3,216,899.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Castle Biosciences news, COO Kristen M. Oelschlager sold 2,793 shares of Castle Biosciences stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $22.06, for a total value of $61,613.58. Following the sale, the chief operating officer now owns 145,825 shares of the company’s stock, valued at approximately $3,216,899.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kristen M. Oelschlager sold 12,989 shares of Castle Biosciences stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $23.06, for a total value of $299,526.34. Following the completion of the sale, the chief operating officer now directly owns 132,836 shares in the company, valued at $3,063,198.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,665 shares of company stock worth $828,222 in the last quarter. Company insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on CSTL shares. Robert W. Baird lifted their target price on Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th. Stephens reiterated an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a research report on Tuesday, August 6th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences has a consensus rating of “Buy” and a consensus target price of $32.80.

Castle Biosciences Stock Performance

Shares of CSTL stock opened at $29.35 on Friday. The stock has a market capitalization of $810.27 million, a PE ratio of -25.52 and a beta of 1.03. Castle Biosciences, Inc. has a 52-week low of $12.07 and a 52-week high of $32.53. The stock’s 50-day moving average price is $28.09 and its 200 day moving average price is $23.84. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.47. The firm had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. Castle Biosciences had a negative return on equity of 0.77% and a negative net margin of 1.08%. During the same quarter in the previous year, the firm posted ($0.70) EPS. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.